au3bvrtk | Knowledge4COVID-19

Property	Value
?:abstract	Remdesivir, a drug with provisional approval for the treatment of COVID-19, is not recommended in patients with an estimated glomerular filtration rate [≤] 30 mL/min. Here we provide a first detailed pharmacokinetic assessment of remdesivir and its major metabolites in a patient with end stage renal disease on hemodialysis.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/au3bvrtk_hasAnnotation_C0013227> <https://research.tib.eu/covid-19/entity/au3bvrtk_hasAnnotation_C0870883>
?:creator	<https://research.tib.eu/covid-19/entity/Soergel%2C_F.%3B_Malin%2C_J._J.%3B_Hagmann%2C_H.%3B_Kinzig%2C_M.%3B_Bilal%2C_M.%3B_Eichenauer%2C_D._A.%3B_Scherf-Clavel%2C_O.%3B_Simonis%2C_A.%3B_El_Tabei%2C_L.%3B_Fuhr%2C_U.%3B_Rybniker%2C_J.>
?:doi	10.1101/2020.10.28.20216887
?:doi	<https://research.tib.eu/covid-19/entity/10.1101/2020.10.28.20216887>
?:license	medrxiv
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/au3bvrtk_HAS_C0013227_TREATS_C5203670>
?:source	MedRxiv; WHO
?:title	Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent hemodialysis
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-11-03

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/au3bvrtk>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/au3bvrtk>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all